Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garetosmab in Fibrodysplasia Ossificans Progressiva
NCT05394116Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of garetosmab in fibrodysplasia ossificans progressiva (FOP), sponsored by Regeneron Pharmaceuticals. Started Nov 2022; status: active, not recruiting.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT05394116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394116.